ANL (Adlai Nortye) Other Current Payables: $0.58 Mil (As of Dec. 2025)


What is Adlai Nortye Other Current Payables?

Adlai Nortye ANL -8.78% Other Current Payables is $0.58 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye's Other Current Payables for the quarter that ended in Dec. 2025 was $0.58 Mil.

Adlai Nortye's quarterly Other Current Payables increased from Dec. 2024 ($0.28 Mil) to Jun. 2025 ($4.88 Mil) but then declined from Jun. 2025 ($4.88 Mil) to Dec. 2025 ($0.58 Mil).

Adlai Nortye's annual Other Current Payables declined from Dec. 2023 ($0.30 Mil) to Dec. 2024 ($0.28 Mil) but then increased from Dec. 2024 ($0.28 Mil) to Dec. 2025 ($0.58 Mil).

Adlai Nortye Other Current Payables Related Terms

Adlai Nortye Other Current Payables Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Other Current Payables Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
0.74 0.25 0.30 0.28 0.58

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only 0.30 3.79 0.28 4.88 0.58

Adlai Nortye Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.58 Mil mean?
Adlai Nortye (ANL) has a Other Current Payables of $0.58 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Other Current Payables too high?
Adlai Nortye's current Other Current Payables is $0.58 Mil.
How does Adlai Nortye's Other Current Payables compare to OMER and PRME?
Adlai Nortye's Other Current Payables of $0.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Other Current Payables is $0.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Other Current Payables of $0.58 Mil. The current Other Current Payables is $0.58 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Other Current Payables is $0.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.